BRAF and acute myeloid leukemia: However, while the case of BRAF V600E-mutant therapy-related AML described by Wander et al. possessed a KMT2A rearrangement, the four cases reported by Xu et al. arose de novo and lacked this cytogenetic finding [1,5].